Cargando...
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
INTRODUCTION: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation an...
Guardado en:
| Publicado en: | Expert Opin Emerg Drugs |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7526049/ https://ncbi.nlm.nih.gov/pubmed/31755325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2019.1696773 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|